Evaxion Expands AI-Immunology Platform to Autoimmune Diseases — Evaxion A/S

Event summary

Evaxion is applying its AI-Immunology™ platform to develop treatments for autoimmune diseases, expanding beyond its current focus on cancer and infectious diseases.
The company is testing two novel treatment concepts: a tolerogenic vaccine and an autoantibody binder, aiming for higher efficacy and fewer side effects.
Initial experimental data will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe on November 18, 2026.
Evaxion's AI-Immunology™ platform is designed to address underlying disease pathologies with high specificity.

The big picture

Evaxion's expansion into autoimmune diseases marks a strategic shift from its traditional focus on cancer and infectious diseases. This move aligns with broader industry trends towards AI-driven drug discovery and personalized medicine, potentially positioning Evaxion as a key player in addressing high unmet medical needs in autoimmune conditions. The company's ability to develop treatments with higher efficacy and fewer side effects could attract significant partnership interest and investment.

What we're watching

Technical Validation: How the experimental data presented at PEGS Europe will validate Evaxion's novel treatment concepts for autoimmune diseases.
Market Potential: Whether Evaxion can leverage its AI-Immunology™ platform to capture significant market share in the autoimmune disease treatment space.
Partnership Opportunities: The pace at which Evaxion can secure partnerships for its autoimmune disease treatments, given the high unmet medical need in this area.